Nasdaq · CIK 0000842023 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
BIO-TECHNE Corp
TECH chart by TradingView
PRICE HISTORY
LIVE · NASDAQTECH chart by TradingView
- REVENUE FY2025 ENDED JUN 2025
- $1.2B
- EBITDA
- $0.2B
- FREE CASH FLOW
- $0.3B
- EPS
- $0.46
- GROSS MARGIN
- 64.80%
- ROIC
- —
Q3 FY26ENDED MAR 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
75.1x
+86%39.4x130.4x
⤢
P / SALES (TTM)
6.8x
-19%6.7x20.7x
⤢
P / BOOK
3.9x
-18%3.9x12.5x
⤢
EV / EBITDA (TTM)
—
-8%30.2x57.6x
⤢
EV / REVENUE (TTM)
—
+7%9.7x20.5x
⤢
FCF YIELD (TTM)
3.28%
+0.3pp1.45%3.39%
⤢
DIVIDEND YIELD (TTM)
0.61%
-0.0pp0.11%0.68%
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.3B
+131%⤢
EBITDA (DERIVED)
$0.1B
+69%⤢
NET INCOME
$0.1B
+99%⤢
EPS (DILUTED)
$0.32
+89%⤢
REVENUE GROWTH YOY
-1.51%
-16.0pp-8.26%47.31%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
24.91%
-0.0pp7.75%42.74%
⤢
RETURN ON CAPITAL
—
+5.2pp8.56%19.36%
⤢
RETURN ON EQUITY (TTM)
5.25%
-6.6pp3.83%17.25%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN66.88%
OPERATING MARGIN24.24%
NET MARGIN16.39%
FCF MARGIN24.91%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.1B
+131%⤢
STOCK-BASED COMP
$0.0B
+281%⤢
CAPITAL EXPENDITURE
$0.0B
+198%⤢
SHARES OUTSTANDING
0.16B
+6%⤢
DIVIDEND / SHARE
$0.08
-0%BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.2B
+227%⤢
TOTAL DEBT
—
+0%⤢
DEBT / EBITDA (TTM)
—
-49%0.0x0.1x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 115.51%INSIDERS 0.32%OTHER / RETAIL 0.00%783 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 7.83% | 12.3M | $886.6M | +1.1% |
| Vanguard Capital Management LLC | 6.50% | 10.2M | $735.9M | NEW |
| Morgan Stanley | 5.45% | 8.5M | $616.8M | +2.3% |
| FMR, LLC | 5.05% | 7.9M | $571.1M | +678.3% |
| Vanguard Portfolio Management LLC | 4.14% | 6.5M | $468.5M | NEW |
| State Street Corporation | 3.75% | 5.9M | $424.2M | +1.0% |
| Wellington Management Group, LLP | 3.27% | 5.1M | $370.1M | -10.7% |
| Geode Capital Management, LLC | 3.27% | 5.1M | $369.6M | +3.7% |
| Maverick Capital Ltd. | 3.03% | 4.7M | $342.6M | +23.1% |
| Invesco Ltd. | 2.93% | 4.6M | $331.7M | +24.7% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.